Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $8.86

Replimune Group, Inc. (NASDAQ:REPL) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.4286.

REPL has been the subject of several recent analyst reports. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a research note on Tuesday, June 30th. Finally, HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. EcoR1 Capital LLC bought a new position in shares of Replimune Group during the 1st quarter worth approximately $7,650,000. Seven Fleet Capital Management LP bought a new stake in Replimune Group in the 1st quarter valued at $921,000. Jefferies Financial Group Inc. acquired a new stake in Replimune Group during the 4th quarter valued at $6,942,000. Candriam S.C.A. acquired a new stake in Replimune Group during the 1st quarter valued at $3,014,000. Finally, Persistent Asset Partners Ltd bought a new position in Replimune Group during the fourth quarter worth $598,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $11.83 on Thursday. The stock has a market capitalization of $994.03 million, a price-to-earnings ratio of -3.50 and a beta of 0.88. The business has a 50-day moving average of $9.92 and a 200-day moving average of $7.47. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.86.

Replimune Group (NASDAQ:REPL) last released its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, sell-side analysts predict that Replimune Group will post -2.54 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.